

Available online at www.sciencerepository.org

Science Repository



Case Report

West Virginia Resident is First American to Receive Dicycloplatin Chemotherapy: A WVU Urologic Oncology Case Report

Mohamad Salkini¹, Chad Morley¹, Chad Crigger¹, Shunchang Jiao² and Jing Jie Yu^{3*}

¹Department of Urology, School of Medicine, WVU, Morgantown, WV, U.S.A

²Oncology Department of Internal Medicine, PLA Hospital, Beijing, China

³WVU Cancer Institute, School of Medicine, and School of Pharmacy, West Virginia University, Morgantown, WV, U.S.A

ARTICLE INFO

Article history:

Received 24 June, 2018

Accepted 6 July, 2018

Published 16 July 2018

Keywords:

Platinum Chemotherapy

Dicycloplatin

Tolerable Side Effects

Bladder Cancer

ABSTRACT

A 65-year-old Caucasian male presented with increasing hematuria over four months in 2016. Work up and scans revealed a 1.5 cm bladder mass, with a subsequent pathologic diagnosis of non-invasive high-grade papillary urothelial carcinoma. The patient declined BCG Immunotherapy and traveled to China soon after diagnosis and transurethral resection for Dicycloplatin (DCP) chemotherapy. DCP is approved by the Chinese FDA but only available at present in military hospitals. It is similar in molecular structure to platinum-based chemotherapy drugs used in the West, its side effects reported to be more tolerable. The patient received 8 weeks of IV DCP chemotherapy – he only experienced mild nausea, myalgia, a relative leukopenia and thrombocytopenia (though within normal limits) and, importantly, no alopecia – then returned to WV for quarterly surveillance. No recurrence of tumor has been observed to date; the most recent cystoscopy was on April 24, 2018, 22 months after diagnosis and resection.

© 2018 Jing Jie Yu. Hosting by Science Repository.

Introduction

The rate of cancer death in the United States for men and women combined fell 25% from its peak in 1991 to 2014. This decline translates to the prevention of millions of cancer deaths. That is significant progress; however, 1,685,210 new cancer cases and 595,690 cancer deaths are projected in the USA in 2016 [1, 2].

Bladder cancer (BC) causes 170,000 deaths annually worldwide. More than 50,000 men and 16,000 women are diagnosed each year in the USA [3,4]. Although quitting smoking lowers the risk, former smokers are likely always at a higher risk of BC versus never smokers [5-7]. Approximately 70 percent of new urothelial bladder cancer cases are non-muscle invasive tumors, typically removed by complete transurethral resection. To prevent recurrence of non-muscle invasive

tumors (T1, Ta), resection is typically followed by intravesical immunotherapy with Bacillus Calmette–Guérin (BCG) if the tumor was high-grade urothelial carcinoma or in the event of large tumors or multifocal disease. BCG is the standard protocol. Some studies suggest that BCG is superior to standard chemotherapy. However, rate of recurrence after adjuvant BCG treatment in bladder cancer is about 50% (90% without BCG) [8-13]. Untreated non-invasive tumors may infiltrate the muscular wall, requiring cystectomy and urinary diversion into an isolated bowel loop or substitute bladder. For muscle invasive BC, the standard treatment is partial or radical cystectomy depending on tumor number and size [14-17].

Platinum drugs remain a cornerstone of chemotherapy for many cancers, including bladder cancer when immunotherapy fails to secure remission. However, the adverse effects of cisplatin and carboplatin are often

*Correspondence to: Jing Jie Yu, MD, WVU Cancer Institute, P.O. Box 9300, Morgantown, WV 26506 USA; Tel: (304) 293-8661; Fax: (304) 293-4667; E-mail: jyu@hsc.wvu.edu

severe, causing some patients to stop treatment. Toxic effects such as myelosuppression, nephrotoxicity, hepatotoxicity, neurotoxicity, and nausea and vomiting are often constraints to full dosage and long-term use.

Dicycloplatin (DCP) is a novel platinum analog developed in China. It was approved by the State Food and Drug Administration (SFDA) of China in March of 2012. DCP is synthesized from platinum powder and contains a host part which is carboplatin and the guest part, an additional carboxylate ligand, linked via 4 hydrogen bonds. It is a hydrogen-bond supramolecule, not a covalent-bond molecule. DCP has a stable chemical structure, good water solubility, and an excellent safety profile [18, 19].

Case Report

A 65-year-old Caucasian American male with increasing hematuria over a 4-month period, without lower urinary tract symptoms, was seen in June of 2016 at West Virginia University (WVU) Hospital, Morgantown, WV, USA. Work-up, including CT-Urogram and cystoscopy revealed a 1.5 cm bladder mass. Transurethral resection was performed on June 30, 2016. The pathologic diagnosis was non-invasive high-grade papillary urothelial carcinoma involving the right lateral wall bladder tumor (Ta). Immunotherapy with BCG and surveillance cystoscopy were recommended to the patient. The patient declined BCG treatment course but elected cystoscopic surveillance every three months at WVU after dicycloplatin chemotherapy in Beijing, China [20].

Of note, the patient is a former smoker. His mother died of ovarian cancer at age 50 and his father had advanced prostate cancer at the time of his death at age 81 from other causes. The patient's family history and his familiarity with DCP through his work as a medical writer led him to elect DCP. In July 2016, the patient traveled to Beijing where he received eight weekly DCP IV infusions.

Baseline blood counts and chemistry were evaluated prior to chemotherapy, then weekly before each treatment. The DCP treatment at Beijing 301 Hospital began July 21, 2016. Dicycloplatin 300 mg was dissolved in 250 ml 5% glucose solution and infused over one hour. The patient was treated in the Day Ward of the Tumor Building at Beijing 301 Hospital and observed for 30 min afterwards. The patient received one cycle of 300 mg of DCP by IV weekly for eight weeks.

Adverse effects of DCP in this patient included mild nausea at the outset, moderate fatigue, and (in the last 2-3 weeks) back and leg aches. There was no emesis or hair loss. Weekly hematological monitoring showed mild effects on blood cells. Noticeable decreases in red blood cells, white blood cells, and platelets were observed. However, all remained within normal limits (Figure 1).

After completion of DCP treatment, the patient returned to the United States for regular surveillance at West Virginia University Hospital. CT IVP was performed on August 3, 2017, thirteen months after resection; no upper tract or metastatic lesions were visualized. Cystoscopies every 3 months up to April 24, 2018 showed no evidence of tumor recurrence.



Figure 1: Hematologic Data - CBC with Differential (July-Sept. 2016 in Beijing 301 Hospital, China)

Cystoscopies performed on October 13, 2016, January 16, 2017, April 20, 2017, August 3, 2017 and on April 24, 2018 revealed no recurrence of tumor, and the resection area was observed to be clear of new growth on each occasion. Wash solutions collected during each cystoscopy were examined by a Cytologist and no malignant cells were observed.

Figure 2 shows the images taken during cystoscopy before resection (top left panel) and after resection (top middle panel) on June 30, 2016. The residue of bladder tumor lesion observed 1-year after DCP treatment is shown in the top right panel, and during the 22-month post DCP chemotherapy in the bottom panels. The resection site appeared to be healing. The DCP chemotherapy received by this patient – and follow-up observations of his resection site - may not prove DCP efficacy is superior. However, the patient only received DCP chemotherapy during his course of treatment since diagnosis, and there is no evidence to date of tumor recurrence. Also, of note, the patient experienced tolerable side effects during DCP chemotherapy.



Figure 2: Cystoscopy Images of Bladder Tumor and Resection Site. Images taken during cystoscopy before and after tumor resection, 1-year after DCP chemotherapy and 22-month follow-up.

Conclusion

DCP has sustained remission in this patient with bladder cancer for more than 22 months. The adverse effects profile was tolerable with minimal myelosuppression.

Acknowledgements

The authors thank Michael D. Mueller for his special contributions to this research and for editorial assistance.

Conflict of interest

The authors declare that they have no competing interests.

REFERENCES

1. The American Cancer Society (2016). Cancer facts and figures.
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, et al. (2012) "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010". *Lancet* 380: 2095-2128. [[Crossref](#)]
3. University of Rochester Medical Center (2007) "Scientists Find One Reason Why Bladder Cancer Hits More Men".
4. Kassouf W, Aprikian A, Black P, Kulkarni G, Izawa J, et al. (2016) Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. *Can Urol Assoc J* 10: E46-80. [[Crossref](#)]
5. Hemelt M, Yamamoto H, Cheng KK, Zeegers MP (2000) The effect of smoking on the male excess of bladder cancer: A meta-analysis and geographical analyses. *Int J Cancer* 2000 124: 412-419. [[Crossref](#)]
6. Zeegers MP, Tan FE, Dorant E, van Den Brandt PA (2000) The impact of characteristics of cigarette smoking on urinary tract cancer risk: A meta-analysis of epidemiologic studies. *Cancer* 89: 630-639. [[Crossref](#)]
7. van Osch FH, Jochems SH, van Schooten FJ, Bryan RT, Zeegers MP (2016) Quantified relations between exposure to tobacco smoking and bladder cancer risk: A meta-analysis of 89 observational studies. *Int J Epidemiol* 45: 857-870. [[Crossref](#)]
8. Alexandroff AB, Jackson AM, O'Donnell MA, James K (1999) "BCG immunotherapy of bladder cancer: 20 years on". *Lancet* 353: 1689-1694. [[Crossref](#)]
9. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K (2005) Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. *J Urol* 174: 86. [[Crossref](#)]
10. Martínez-Piñero JA, Jiménez León J, Martínez-Piñero L Jr, Fiter L, Mosteiro JA, et al. (1990) Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. *J Urol* 143: 502. [[Crossref](#)]
11. Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, et al. (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. *Cochrane Database Syst Rev* CD003231. [[Crossref](#)]
12. Böhle A, Jocham D, Bock PR (2004) Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal metaanalysis of comparative studies on tumor progression. *Urology* 63: 682. [[Crossref](#)]
13. de Reijke TM, Kurth KH, Sylvester RJ, Hall RR, Brausi M, et al. (2005) Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906). *J Urol* 173: 405-409. [[Crossref](#)]
14. European Association of Urology (EAU)—Guidelines—Online Guidelines (2013) Uroweb.org.
15. Hall R (2002) Updated results of a randomised controlled trial of neoadjuvant cisplatin (C), methotrexate (m) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer. *Proc Am Soc Clin Oncol* 21: 178A.
16. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, et al. (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. *N Engl J Med* 349: 859-866. [[Crossref](#)]
17. Hall R (2002) Updated results of a randomised controlled trial of neoadjuvant cisplatin (C), methotrexate (m) and vinblastin (V) chemotherapy for muscle-invasive bladder cancer. *Proc Am Soc Clin Oncol*. 21:178A.
18. Yu JJ, Yang XQ, Song QH, Mueller MD, Remick SC (2014) Dicycloplatin, a novel platinum analog in chemotherapy: Synthesis of Chinese preclinical and clinical profile and emerging mechanistic studies. *Anticancer Research* 34: 455-464. [[Crossref](#)]
19. Yang XQ, Yu JJ, Guo Y, Mueller MD (2017) Dicycloplatin, a Platinum - Based Supramolecule with 4 Hydrogen Bonds, is a Promising Chemotherapy Drug: Frontiers in Clinical Drug Research - Anti-Cancer Agents. Atta-ur-Rahman (Ed.) Bentham Science Publishers, Sharjah, United Arab Emirates.
20. Yu JJ, Salkini MW, Jiao S, Hogan T, Guo Y, et al. (2017) The first American cancer patient to receive dicycloplatin chemotherapy: A case report. *J Cancer Res Ther* 5: 56-60.